SABBY MANAGEMENT, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.

Quarter-by-quarter ownership
SABBY MANAGEMENT, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$27,310
-98.7%
136,484
-73.4%
0.02%
-93.3%
Q4 2021$2,053,000
+30.6%
513,211
+7.7%
0.30%
+40.6%
Q3 2021$1,572,000
+70.3%
476,325
+96.1%
0.21%
+63.1%
Q2 2021$923,000
+76.5%
242,850
+77.8%
0.13%
+27.5%
Q1 2021$523,000
-16.3%
136,610
-13.6%
0.10%
-87.0%
Q2 2019$625,000
-80.7%
158,152
-78.8%
0.79%
-49.4%
Q1 2019$3,234,000
-9.9%
745,205
-26.3%
1.55%
+97.0%
Q4 2018$3,588,000
+3.5%
1,010,682
+11.4%
0.79%
+78.1%
Q3 2018$3,465,000
-4.4%
906,956
-2.4%
0.44%
-20.9%
Q2 2018$3,626,000
+2490.0%
929,725
+1982.4%
0.56%
+6900.0%
Q1 2018$140,000
+100.0%
44,646
+166.8%
0.01%
+60.0%
Q2 2017$70,000
-89.0%
16,731
-93.3%
0.01%
-86.5%
Q4 2016$637,000
-40.0%
250,766
-43.6%
0.04%
-7.5%
Q3 2016$1,062,000
-7.6%
444,500
-6.8%
0.04%
-33.3%
Q2 2016$1,149,000
-12.8%
476,719
-3.3%
0.06%
-9.1%
Q1 2016$1,317,000
-40.2%
493,191
-35.9%
0.07%
-45.5%
Q4 2015$2,201,000
+12.8%
769,534
-9.7%
0.12%
+51.2%
Q3 2015$1,952,000
-27.3%
852,348
+14.6%
0.08%
-18.4%
Q2 2015$2,685,000
-57.2%
743,647
-47.2%
0.10%
-62.5%
Q1 2015$6,272,000
+88.8%
1,409,537
+74.4%
0.26%
+103.9%
Q3 2014$3,322,000808,2560.13%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2021
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders